Layden-Almer Jennifer E, Kuiken Carla, Ribeiro Ruy M, Kunstman Kevin J, Perelson Alan S, Layden Thomas J, Wolinsky Steven M
Department of Medicine, University of Illinois at Chicago, 60612, USA.
J Infect Dis. 2005 Sep 15;192(6):1078-87. doi: 10.1086/432760. Epub 2005 Aug 12.
In hepatitis C virus (HCV) infection, race is a determinant of treatment response and interferon (IFN) effectiveness. Here, we investigated whether there were differences in the pretreatment viral strains between African American patients and white patients and whether these differences correlated with viral kinetics. IFN effectiveness was calculated using a viral kinetic model. The HCV NS5A region from 21 treated patients with HCV genotype 1a was sequenced and analyzed. White patients displayed more mutations in the V3 region (mean+/-SD, 4.5+/-1.4 vs. 2.9+/-1.6; P=.016), and treatment responders tended to have more mutations in this region than did nonresponders. There was a significant positive correlation between IFN effectiveness and the number of mutations in the V3 region (P=.03). There was no clustering of strains by race, treatment response, or IFN effectiveness in phylogenetic analyses. The results of this study, in conjunction with those of a previous study illustrating the impaired IFN effectiveness in African Americans, suggest a role for host-related factors.
在丙型肝炎病毒（HCV）感染中，种族是治疗反应和干扰素（IFN）疗效的一个决定因素。在此，我们调查了非裔美国患者和白人患者治疗前病毒株是否存在差异，以及这些差异是否与病毒动力学相关。使用病毒动力学模型计算IFN疗效。对21例接受治疗的HCV 1a基因型患者的HCV NS5A区域进行测序和分析。白人患者在V3区域显示出更多突变（均值±标准差，4.5±1.4对2.9±1.6；P = 0.016），且治疗反应者在该区域往往比无反应者有更多突变。IFN疗效与V3区域突变数量之间存在显著正相关（P = 0.03）。在系统发育分析中，未发现按种族、治疗反应或IFN疗效聚类的毒株。本研究结果与先前一项说明非裔美国人中IFN疗效受损的研究结果相结合，提示宿主相关因素发挥了作用。
